Posts Tagged ‘Campath’



Novartis announces a major US reorganization, including re-aligned business units, and cuts. Ouch.

Crystal ball – what will be the biggest drug(s) in 2014? Here are some educated guesses.

Use Remicade early in Crohn’s, the results say – “The results are pretty definitive,” Sandborn told MedPage Today. “Most patients should receive infliximab combination therapy as the most effective strategy.“…more

Genzyme‘s Campath for MS:  preliminary data look quite promising – Data presented on Wednesday at the annual meeting of the American Academy of Neurology showed that after four years, 71 percent of patients had no relapse or worsening of disability. That compares with 35 percent for patients taking Rebif, a rival drug made by EMD Serono, an affiliate of Germany’s Merck KGaA and Pfizer Incmore


ANY Pharma sales training – The Impactiviti Partner Network is your resource if you’re looking for a great training provider. We “matchmake” best-in-class partners to meet your training needs – at no cost to you!  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.


I’m Restless – how about you?


Come out of your shell. Cool photos – just trust me and look.


Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)


Read Full Post »

Solvay shopping its drug business. Belgian conglomerate Solvay is eying an exit of the drug business with a sale of its pharmaceutical division that could be worth upwards of €5 billion, or $6.6 billion. Solvay didn’t go into details about why it might give up its fastest-growing and most profitable division. But after talk of a deal involving Solvay, the company issued a statement Wednesday saying it was exploring “various options for its pharmaceutical activities,” and that this review involves “discussions with third parties.”

Watson wins an important round with J&J on Concerta going generic.

Genzyme takes over rights to MS and Oncology drugs from Bayer HealthCare – Genzyme has scooped up key worldwide rights to the leukemia drug Campath–which is being studied as a treatment for MS–and two cancer therapies from its development partner Bayer HealthCare in a deal with a potential $2.8 billion payout.


Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

Sanofi-Aventis suspends sale of Acomplia in Europe. Acomplia, an obesity drug that once looked like it would be a blockbuster for Sanofi-Aventis, is being pulled off the market in Europe. The EMEA, the European version of the FDA, said today that a key committee “concluded that the benefits of Acomplia no longer outweigh its risks and the marketing authorisation should be suspended across the European Union.”…more

Jim Edwards summarizes what he calls Pfizer‘s Race to the Bottom. With some similar commentary on Novartis‘ growth/shrinkage.

Merck announces more big cuts – As part of its earnings announcement, the drugmaker says it expects to eliminate approximately 7,200 positions – 6,800 active employees and 400 vacancies – across all areas of the company worldwide by the end of 2011, with about 40 percent of the total reductions coming in the US (see statement). This amounts to 12 percent of the workforce…more

Pfizer’s Chantix: going down…or up, depending on which continent you’re on…US researchers say even more warnings needed.

FDA: Another day, another stall – U.S. regulators have extended by three months their review of a proposed osteoporosis drug from Pfizer Inc to study the pill in more depth, a company spokeswoman said on Tuesday…more And, while we’re at it, a thumbs down (for now) for Abbott‘s new version of Vicodin. Oh, and hey, let’s delay Abbott’s new cholesterol drug while we’re in foot-dragging mode!

Novartis buys up Nektar’s pulmonary business – Nektar Therapeutics  today announced that Novartis AG has agreed to acquire from Nektar specific pulmonary delivery assets, technology, and intellectual property for $115 million in cash…more

Will BMS lead the charge in buying up undervalued biotechs?

Earnings roundup for Schering, Pfizer, Roche here’s the scoop.

What about Amgen’s growth? An interesting analysis here. Plus – how 6 pharma companies have dodged (or not) the current financial crisis (extracts from earnings announcements from Pfizer, Bayer, Abbott Labs, Gilead, Wyeth and Genentech, all on the topic of how each company has fared in the crisis.)

Celgene seems to be doing quite OK.

J&J’s HIV drug gets expanded approval – U.S. health regulators have expanded approval for Johnson & Johnson’s Prezista in combination with other drugs to treat HIV patients who are just beginning to take medication for the virus, the company said on Wednesday…more

Avastin: what doesn’t this drug do? – After tagging the antibody drug with a radioactive tracer and injecting it into mice, researchers found it successfully targeted cancer cells and this enabled them to produce well-defined images of tumours during scanning…more

Speaking of which, does leukemia drug Campath help stop early stage MS? Fascinating possibility – A drug developed to fight leukemia appears to stop multiple sclerosis in its early stages and restore lost function to patients, British researchers said on Wednesday…more

Forest Labs growing green – Forest Laboratories Inc posted higher-than-expected quarterly profit on Tuesday, fueled by stronger sales of its drugs for Alzheimer’s disease and depression and lower research spending…more

Biologics and safety concerns: really not a big surprise here – Approximately one in four biologics approved since 1995 in the US and Europe have had at least one safety-related regulatory action issued for them 10 years after their approval, including about 11 percent receiving a Black Box warning, according to a study in the Journal of the American Medical Association…more

Take a Chill, Pill: are oral cancer drugs all they’re cracked up to be?

B-I has some encouraging potential early results for novel cancer drugs.

The WSJ talks about healthcare, IT, and the future. Interesting stuff.

Reblog this post [with Zemanta]

Read Full Post »